Evidence map›Paper›PMID 39926208›Full record

ArticleBiochemistry and biophysics reports2025

Development of a general anti-viral therapeutic using cholestosome technology to exploit inhibition of intracellular viral production.

Lawrence Mielnicki, Julie Hughes, Mary Irving, Mary McCourt

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lawrence MielnickiDepartment of Chemistry, Biochemistry and Physics, Niagara University, Lewiston, NY, 14109, USA.
Julie HughesDepartment of Chemistry, Biochemistry and Physics, Niagara University, Lewiston, NY, 14109, USA.
Mary IrvingDepartment of Chemistry, Biochemistry and Physics, Niagara University, Lewiston, NY, 14109, USA.
Mary McCourtDepartment of Chemistry, Biochemistry and Physics, Niagara University, Lewiston, NY, 14109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent events of the worldwide Covid-19 pandemic showed the need for a general anti-viral therapeutic, independent of the specific characteristics of the virus, that targets intracellular mechanisms of viral production to prevent the rapid, overwhelming spread of infection and its devastating consequences. The development of the Cholestosome technology, a drug delivery system made exclusively of cholesteryl esters, is a solution for intracellular targeting of viral replication. It is well known that Zn

Identifiers

PMID39926208
PMCPMC11803885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.